Membership
Current Officers
All Members
| Maysaa Abdallah (Egypt) |
| Abdul Ridha Al Abbasi (Iraq) |
| Shafiqul Bari (Bangladesh) |
| Junaid Bhai (Bangladesh) |
| Rehab Elsaid (Egypt) |
| Mohamad S. Hakim (Indonesia) |
| Noha Hammad (Egypt) |
| Hakan Leblebicioglu (Turkey) |
| Mai Maamoun (Egypt) |
| Mojca Matičič (Slovenia) |
| Syed Ghulam Mogni Mowla (Bangladesh) |
| Monkez Moteia (Egypt) |
| Kurt Naber (Germany) |
| Ghada Nasr (Egypt) |
| Fazle Rabbi Chowdhury (Bangladesh) |
| Alfonso J. Rodríguez-Morales (Colombia) |
| Alpaslan Tangolu (Turkey) |
How to Join
ISAC Working Groups are open to new members with a strong interest and relevant experience in the given field. To join an ISAC Working Group, please contact Fee Johnstone, ISAC Executive Officer secretariat@isac.world with your name and a brief C.V. We welcome new members!
Aims and Objectives
Viral infections are spread worldwide and result in significant morbidity and mortality. Globally, viral hepatitis is of particular concern as it was the seventh leading cause of death in 2013, up from the 10th leading cause in 1990. The most important hepatitis viruses are hepatitis B and C. About 2 billion people in the world have evidence of past or current HBV infection, with 240 million chronic carriers of HBsAg. HBV leads to 650,000 deaths annually as a result of viral hepatitis–induced liver disease. An estimated 71 million people are chronically infected with HCV worldwide. About 55-85% of these people infected progress to chronic HCV infection, with a 15-30% risk of developing liver cirrhosis within two decades. Approximately 399,000 people die each year from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma. Antiviral medicines can cure more than 95% of persons with hepatitis C infection, thereby reducing the risk of death from liver cancer and cirrhosis, but access to diagnosis and treatment is low. Hepatitis can also result from infection by other A- E hepatitis and fourteen other families of viruses.
Aim of the Viral Infection Working Group
To work together at an international level, in multiple areas related to viral infections with regards to education and research activities. Participation of junior colleagues in all activities is strongly encouraged.
Objectives
1. To hold “Viral/Hepatitis Symposiums” in all future meetings whether national, regional or international.
2. To carry out relevant research activities.
3. To carry out a series of “post graduate courses in viral infections”.
4. To link and synergize with other medical societies and stakeholders working around viral infections
Webinars
AIMS
1. To raise awareness of various aspects related to rabies for healthcare workers, vets and all other professionals involved, directly or indirectly, with rabies.
2. Demonstrate how we can combat rabies.
OBJECTIVES
1. Describe rabies virology and vaccination.
2. Discuss global epidemiology of the disease.
3. Specify the importance of different animal reservoirs in the spread of the virus.
4. Explain the One Health perspective in eliminating rabies, emphasising the role of new technology as tools in this process.
-----------------------------------------------------------------
Dissemination of viral infections during mass gatherings
October 2022
The purpose of this webinar was to outline the most significant viral infections currently associated with mass gatherings, suggest key planning considerations for the organisers of mass gatherings in the context of novel viral outbreaks and provide general advice on the public health aspects of mass events.
Publications
|
Grasping knowledge, attitude, and perception towards monkeypox among healthcare workers and medical students: an Egyptian cross-sectional study |
|
Mpox: Risks and approaches to prevention |
|
Assessment and outcome of hospitalized patients during delta variant COVID-19 pandemic: A multicenter international study |
|
Zero by 2030 and OneHealth: The multidisciplinary challenges of rabies control and elimination |
|
Monkeypox virus infection in women and non-binary people: uncommon or neglected? |
| FIFA World Cup 2022 in Qatar: Mitigating the risk of imported infections amid the COVID-19 pandemic, monkeypox outbreak and other emerging diseases Sah R, Alshahrani NZ, Shah P et al Travel Medicine and Infectious Disease, Volume 50, 2022, |
| A Potential Monkeypox Pandemic: Are We Making the Same Mistakes as COVID-19? Sah R, Reda A, Abdelaa A et al New Microbes and New Infections, https://doi.org/10.1016/j.nmni.2022.101030 |
| Growing shreds of evidence for monkeypox to be a sexually transmitted infection Amer FA, Hamaad, NH, Wegdan A-A et al Infez Med 2022 Sep;30(3) Ahead Jul 3 |
| T- PCR testing of upper respiratory tract samples for diagnosis of SARS-CoV-2: Between justification and overestimation, a multi-center international study Hammad NM, Saeed MA, Shaltout SW et al Travel Med Infect Dis. Jul-Aug 2022;48:102334. |
| Individuals with covert severe acute respiratory syndrome coronavirus 2 infection: Are they a critical booby-trap? Amer FA Rev Soc Bras Med Trop. 2020; 53: e20200231. |
| Surveillance and impact of occult hepatitis B virus, SEN virus, and torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection Amer F, Yousif MM, Mohtady H, et al. Int J Infect Dis. 2020;92:13-18 |
| HCV infection among asymptomatic Egyptian children. In final stage of writing |
|
Epidemiology of Hepatitis C Virus Infection in Egypt Amer FA, Gohar M and Yousef M. International Journal of Tropical Disease & Health. 2015: 7(3): 119-131. |
|
Immunological mechanisms controlling hepatitis C virus infection. Amer FA. Asian Pacific Journal of Tropical Disease. 2015: 5(2): 85-90 |
|
Immune-based strategies for treatment and prevention of hepatitis C virus infection. Amer FA, Mansour MA, Mansour SA. The International Arabic Journal of Antimicrobial Agents. 2014: 1 |
|
Multicenter Study Developing a multicenter study “Real world experience of interferon-based, versus interferon-free therapy of chronic hepatitis C in different ethnic populations” and recruiting participants. |
Future / Ongoing Activities
| Developing E-module on the topic of Hepatitis C for the ISAC Academy. |
| Continuing to develop HCV multicenter study. |
| Working on the possibility of carrying out: a. Another multicenter study b. Postgraduate courses |
Presentations / Symposia
| 7 - 9 November 2019 |
Symposium on viral infections within the 17th European AIDS Conference in Basel, Switzerland |
| November 2019 |
Hepatitis Symposium”, 31st ICC- 4th GCCMID, November2019 – Dubai, UAE. |
| October 2019 |
“Hepatitis Symposium”, 10th SEEC, Budva, Montenegro. |
| March 2019 |
International Forum on Infectious Diseases (IFID) - Istanbul, Turkey. Hepatitis Symposium |
| 23-24 Nov 2018 |
2nd International Conference on Gastroenterology and Hepatology - Bangkok, Thailand. Surveillance and impact of occult hepatitis B virus, SEN virus and TT virus among hemodialysis patients with chronic hepatitis C virus infection in the Eastern Province of Egypt |
| April 2017 |
27th ECCMID - Vienna, Austria. Large-scale hepatitis C combating campaigns in Egypt and Georgia - past, current and future challenges |
|
The Revolution of Treatment of hepatitis C virus by direct acting antivirals; has the story come to the end?
|
|
| March 2016 |
17th International Congress on Infectious Diseases (ICID) - Hyderabad, India. Egyptian experience in the management of HCV infection |
| Nov 2015 |
6th SECC - Thessaloniki, Greece Hepatitis Symposium |
| July 2015 |
World Congress on Hepatitis - Orlando, Florida. Burden of HCV disease in Egypt and efforts to combat |
| Dec 2014 |
3rd National Conference on Tropical Medicine & Toxicology -Sylhet, Bangladesh In the era of direct acting antivirals; is there a need for an HCV vaccine? |
|
Epidemiology of hepatitis C virus infection in Egypt; overt and occult • 5th International Conference of SPIC-EGYPT, 6th International Infection Control Conference of TBRI. November 2014, Cairo, Egypt. |
|
| April 2014 |
3rd conference of FASCMID & 10th Conference of ArAPUA - Dead Sea, Jordan. Direct- acting antivirals; a new horizon in the treatment of hepatitis C virus infections |
Last updated: February 15th-2024
